Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Real-World Analysis Of Ruxolitinib Treatment Patterns And Outcomes Among Patients With Myelofibrosis

Tanya Burton,Kejal Parikh,Manish Patel,Kevin Sundquist,Lincy S. Lal,Ronda Copher,Aaron T. Gerds

BLOOD（2019）

Cited 3|Views11
No score
Abstract
Background: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, cytopenias, and poor survival. Ruxolitinib (RUX) is the only approved treatment for Intermediate or High-risk MF. In a previous study, we have shown almost 1 in 3 patients initiating RUX had dose modifications during the first 3 months of treatment (Burton T et al. HemaSphere 2019). The objective of this study was to assess RUX treatment patterns among patients with MF.
More
Translated text
Key words
Ruxolitinib Therapy,Myelofibrosis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined